Vascular permeability increase as induced by histamine or bradykinin is enhanced by advanced glycation endproducts (AGEs)

Journal of Diabetes and its Complications

Volumn 13, Issue 4, 1999, Pages 187-190

  Svensjö, Erik ^a   Cyrino, Fatima ^b   Michoud, Edouard ^c   Ruggiero, Daniel ^c   Bouskela, Eliete ^b   Wiernsperger, Nicolas ^c  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANTIOXIDANT; BOVINE SERUM ALBUMIN; BRADYKININ; HISTAMINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CHEEK POUCH; CONTROLLED STUDY; DIABETES MELLITUS; EXTRAVASATION; HAMSTER; MALE; NONHUMAN; PRIORITY JOURNAL;

ALBUMINS; ANIMALS; BRADYKININ; CAPILLARY PERMEABILITY; CRICETINAE; DEXTRANS; DRUG SYNERGISM; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENT DYES; GLYCOSYLATION END PRODUCTS, ADVANCED; HISTAMINE; MALE; MESOCRICETUS; MOUTH MUCOSA;

EID: 0032763998     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8727(99)00043-4     Document Type: Article

References (13)

1. Brownlee M. Glycosylation products as toxic mediators of diabetic complications. Annu Rev Med. 42:1991;159-166.
2. Esposito C., Gerlach H., Brett J., Stern D., Vlassara H. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med. 170:1989;1387-1407.
3. Bucala R., Cerami A., Vlassara H. Advanced glycosylation end products in diabetic complications. Diabet Rev. 3:1995;258-268.
4. Brett J., Schmidt A.M., Yan S.D., Zou Y.S., Weidman E., Pinsky D., Nowygrod R., Neeper M., Przysiecki C., Shaw A. Survey of the distribution of a newly characterized receptor for AGEs in tissues. Am J Pathol. 143:1993;1699-1712.
5. Wautier J.-L., Zoukurian C., Chappey O., Wautier M.-P., Guillausseau P.-J., Cao R., Hori O., Stern D., Schmidt A.M. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. J Clin Invest. 97:1996;238-243.
6. Svensjö E. The hamster cheek pouch as model in microcirculation research. Eur Respir J. 3(Suppl 12):1990;595-601.
7. Bouskela E., Cyrino F.Z., Conde C.M., Garcia A.A. Microvascular permeability changes with sulfonyl ureas in normal and diabetic hamsters. Metabolism. 46:1997;26-30.
8. Svensjö E., Bouskela E., Cyrino F.Z.G.A., Bougaret S. Antipermeability effects of Cyclo 3 Fort in hamsters with a moderate degree of diabetes. Clin Haemorheol. 17:1997;385-388.
9. Sampietro T., Bertuglia S., Colantuoni A., Bionda A., Lenzi S., Donato L. Increased permeability of hamster microcirculation to glycosylated albumin. Lancet. 31:1987;994-996.
10. Ruggiero-Lopez D., Rellier N., Lecomte M., Wiernsperger N. Growth modulation of retinal microvascular cells by early and advanced glycation end products. Diabetes Res Clin Pr. 34:1997;135-142.
11. Chappey O., Dosquet C., Wautier M.-P., Wautier J.-L. Advanced glycation end products, oxidant stress and vascular lesions. Eur J Clin Invest. 27:1997;97-108.
12. Schmidt A.M., Hasu M., Popov D.et al. Receptor for AGEs has a central role in vessel wall interactions and gene activation in response to AGE proteins. Proc Natl Acad Sci USA. 91:1994;8807-8811.
13. Renard C., Chappey O., Wautier M.P., Nagashima M., Lundh E., Morser J., Zhao L., Schmidt A.M., Scherrmann J.M., Wautier J.L. Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. Mol Pharmacol. 52:1997;54-62.